JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $95
JonesTrading has reiterated its Buy rating for Spyre Therapeutics (SYRE.US) and maintained a target price of $95. This indicates a continued positive outlook on the company's stock performance from the analytical firm.
UBS Group AG Has $22.30 Million Stake in Spyre Therapeutics, Inc. $SYRE
UBS Group AG significantly increased its stake in Spyre Therapeutics, Inc. (SYRE) by 76.5% in the fourth quarter, reaching a total value of $22.30 million. Other institutional investors like Vanguard and Wellington also raised their positions, leading to institutional ownership of 80.39%. Despite executives selling shares and a slight earnings per share miss, analysts maintain a consensus "Buy" rating for Spyre Therapeutics, with an average target price of $89.08.
Deutsche Bank Adjusts Spyre Therapeutics Price Target to $102 From $86, Maintains Buy Rating
Deutsche Bank has increased its price target for Spyre Therapeutics (NASDAQ: SYRE) to $102 from $86. The firm reiterated its Buy rating on the stock, indicating continued confidence in the company's prospects. This adjustment reflects an updated valuation by Deutsche Bank.
Spyre Therapeutics stock hits 52-week high at $76.56 By Investing.com
Spyre Therapeutics' stock hit a 52-week high of $76.56, currently trading at $76.96, just 1% below its peak. This surge follows a 432% increase over the past year and a 221% rise in the last six months, driven by investor confidence despite warnings of potential overvaluation by InvestingPro. The company recently completed a $463.5 million stock offering and received raised price targets and a "strong buy" rating from analysts like Stifel and Raymond James.
Hot Picks: Biotech stocks gain on cancer drugs and trial data
Biotech stocks are making a strong comeback, fueled by increased merger and acquisition activity and renewed investor confidence. Wedbush senior analyst David Nierengarten highlights Nuvation Bio, Spyre Therapeutics, and Perspective Therapeutics as key players. These companies are advancing treatments for lung cancer, autoimmune diseases, and various cancer types using radiopharmaceuticals, with significant clinical trial data and commercial launches expected to drive further growth.
Spyre Therapeutics stock hits 52-week high at $76.56
Spyre Therapeutics (SYRE) stock has reached a new 52-week high at $76.96, reflecting a significant 432% one-year total return. This surge in investor confidence follows the successful closing of a $463.5 million stock offering and positive analyst ratings, though InvestingPro suggests the stock may be overvalued relative to its Fair Value.
Spyre Therapeutics Insider Sold Shares Worth $5,952,050, According to a Recent SEC Filing
An insider at Spyre Therapeutics (SYRE) recently sold shares valued at $5,952,050, as reported in a recent SEC filing. The article highlights this transaction and provides additional company information, including recent earnings results, stock offerings, and analyst ratings. Spyre Therapeutics is a clinical-stage biotechnology company focused on treatments for inflammatory bowel disease and other immune-mediated conditions.
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $103
LifeSci Capital has reiterated its Buy rating on Spyre Therapeutics (SYRE.US) and maintained its target price at $103. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
Spyre Therapeutics director Michael Henderson sells $5.95 million in shares
Michael Henderson, a director at Spyre Therapeutics (NASDAQ:SYRE), sold approximately $5.95 million worth of common stock on May 8, 2026, through a pre-planned trading arrangement. The sale involved 89,900 shares and occurred while the stock was trading near its 52-week high, with an InvestingPro analysis suggesting it is overvalued. Following these transactions, Henderson directly holds 88,606 shares.
Spyre Therapeutics director Michael Henderson sells $5.95 million in shares
Spyre Therapeutics director Michael Henderson sold approximately $5.95 million worth of common stock on May 8, 2026, under a pre-established trading plan. This sale involved 89,900 shares and occurred as the stock neared its 52-week high after a significant 432% gain over the past year. Henderson now directly holds 88,606 shares in the company.
Spyre Therapeutics (SYRE) director sells 80,000 shares in planned trades
Spyre Therapeutics director Michael Thomas Henderson sold 80,000 shares of common stock on May 8, 2026, through a pre-arranged Rule 10b5-1 trading plan. The sales, totaling approximately $5.95 million, were executed in four separate transactions with weighted average prices ranging from $72.57 to $75.35 per share. Henderson's direct holdings after these transactions are 166,202 shares of common stock.
Spyre Therapeutics, Inc. SEC Filing
This article reports on Spyre Therapeutics, Inc.'s SEC Form 144 filing from May 8, 2026, concerning a proposed sale of 80,000 common shares with an aggregate market value of $5,848,000, acquired via Restricted Stock Units. The filing details the transaction through Morgan Stanley Smith Barney LLC on NASDAQ. It also provides an overview of recent news and financial filings for Spyre Therapeutics.
Spyre Therapeutics | SCHEDULE 13G: Others
This article provides a link to the SCHEDULE 13G filing for Spyre Therapeutics, detailing ownership information by "Others." The document is a regulatory filing that discloses beneficial ownership of a company's stock.
Spyre Therapeutics (Nasdaq:SYRE) - Stock Analysis
Spyre Therapeutics is a clinical-stage biotechnology company focused on inflammatory bowel disease and rheumatic diseases. The company is advancing multiple mid-stage clinical trials for its drug candidates, including SPY001, SPY002, SPY072, and SPY003, with several key data readouts anticipated in 2026. While analysts are optimistic about the stock's potential rise, the company faces risks such as forecasted earnings decline, unprofitability, and prior shareholder dilution.
Spyre Therapeutics: Q1 Earnings Snapshot
Spyre Therapeutics (SYRE) reported a Q1 loss of $69 million, or 74 cents per share, falling short of Wall Street's expectation of a 66-cent loss per share. The Waltham, Massachusetts-based company's results were generated using data from Zacks Investment Research.
Spyre Therapeutics’ Exclusive Forum Clauses Shift Legal Leverage, Raise Venue and Litigation Cost Concerns for Stockholders
Spyre Therapeutics (SYRE) has introduced exclusive forum provisions requiring internal corporate and fiduciary duty claims to be heard in Delaware and Securities Act claims in U.S. federal courts. While this aims to reduce multi-forum litigation, it could limit stockholders' choice of venue and increase their legal costs, shifting legal leverage toward the company. Wall Street currently rates SYRE stock with a Strong Buy consensus based on 16 buy ratings.
Stifel raises Spyre stock price target to $107 on UC data strength
Stifel has increased its price target for Spyre Therapeutics (NASDAQ:SYRE) shares to $107 from $92, maintaining a Buy rating due to strong ulcerative colitis (UC) data for SPY001. The firm highlighted validation from Johnson & Johnson's DUET study and positive commentary from AbbVie supporting the combination therapy thesis in Crohn's disease, with further data readouts for other drug candidates expected in mid-2026 to Q4 2026.
According to the latest financial data from biopharmaceutical company Spyre Therapeutics Inc, as of March 31, 2026, the company's total cash, cash equivalents, and marketable securities amounted to 741.5 millions USD.
Biopharmaceutical company Spyre Therapeutics Inc. reported total cash, cash equivalents, and marketable securities of 741.5 million USD as of March 31, 2026. This strong financial position is expected to support operations until the second half of 2029 and provides a solid foundation for research and development despite the challenging biotechnology financing environment.
Spyre Therapeutics Q1 Loss Widens
Spyre Therapeutics (NASDAQ: SYRE) announced a widening of its Q1 loss compared to the previous year. The company reported a net loss of $1.15 per share for the first quarter of 2024, an increase from $0.66 per share in Q1 2023, while also stating it has sufficient cash to fund operations into 2026.
According to the latest financial data from biopharmaceutical company Spyre Therapeutics Inc, as of March 31, 2026, the company's total cash, cash equivalents, and marketable securities amounted to 741.5 millions USD.
Spyre Therapeutics Inc. reported total cash, cash equivalents, and marketable securities of $741.5 million as of March 31, 2026. This strong financial position is expected to fund operations until the second half of 2029 and support the development of innovative therapies, despite a challenging biotechnology financing environment.
Spyre Therapeutics, Inc. Q1 operating expenses USD 45.641 million
Spyre Therapeutics, Inc. reported its operating expenses for the first quarter ended March 31, 2026, totaling $45.641 million. This financial update follows other recent news for the biotechnology company, including its Q1 earnings results, a widening loss, and significant stock offerings in April 2026. The company is focused on developing inflammatory bowel disease (IBD) products with a pipeline that includes extended half-life antibodies.
Earnings Flash (SYRE) Spyre Therapeutics Posts Q1 Net Loss $0.74 a Share, Vs. FactSet Est of $0.67 Loss
Spyre Therapeutics reported a Q1 net loss of $0.74 per share, which is wider than the FactSet estimate of a $0.67 loss per share. This financial update indicates the company's performance relative to analyst expectations for the first quarter.
Spyre Therapeutics (SYRE) widens Q1 loss but builds $1.18B pro forma cash runway
Spyre Therapeutics reported a net loss of $69.0 million for Q1 2026, an increase from $44.8 million a year prior, due to increased R&D and G&A expenses. Despite the wider loss, the company significantly bolstered its cash reserves to a pro forma $1.18 billion, including proceeds from an April 2026 equity offering, extending its cash runway into the second half of 2029. Additionally, Spyre announced positive topline induction data for SPY001 from its SKYLINE Phase 2 trial, showing potential best-in-class efficacy for ulcerative colitis.
Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Spyre Therapeutics announced its first quarter 2026 financial results, highlighting positive topline data from its Phase 2 SKYLINE trial for SPY001 in IBD, showing best-in-class efficacy potential. The company also reported over-enrollment and accelerated timelines for its SKYWAY trial in rheumatoid arthritis, expecting six proof-of-concept readouts in 2026. Spyre strengthened its balance sheet with $463 million in gross proceeds from a public offering, providing a cash runway into the second half of 2029.
Spyre Therapeutics, Inc. 1Q 2026: Net loss $(69.0)M, EPS $(0.74) — 10-Q Summary
Spyre Therapeutics, Inc. reported a net loss of $(69.0)M for Q1 2026, with a diluted EPS of $(0.74), an increase in loss compared to Q1 2025. The company, a clinical-stage entity with no product revenue, highlighted progress in its SKYLINE and SKYWAY Phase 2 trials for ulcerative colitis and rheumatic diseases, along with advancements in its pipeline candidates. Management confirmed sufficient capital to fund operations for over a year due to recent equity offerings.
Spyre Therapeutics: Q1 Earnings Snapshot
Spyre Therapeutics (SYRE) reported a first-quarter loss of $69 million, or 74 cents per share, according to their Q1 earnings snapshot. These results fell short of Wall Street's expectations, as analysts surveyed by Zacks Investment Research had estimated a loss of 66 cents per share. The financial data was generated by Automated Insights using information from Zacks Investment Research.
Spyre Therapeutics CMO Sheldon Sloan sells $5.6m in shares
Sheldon Sloan, Chief Medical Officer of Spyre Therapeutics, Inc. (NASDAQ:SYRE), sold approximately $5.60 million worth of common stock on May 1, 2026, through a Rule 10b5-1 trading plan. This sale followed his exercise of stock options for 78,333 shares at $27.46 each, and the transactions occurred while the stock was trading near its 52-week high, having surged 359% in the past year. InvestingPro analysis suggests the stock is overvalued, and Sloan now directly holds no common stock but retains derivative securities.
Spyre Therapeutics CFO Scott Burrows sells $892,125 in stock
Spyre Therapeutics CFO Scott L. Burrows sold 12,500 shares of company stock worth $892,125 on May 1, 2026, under a Rule 10b5-1 trading plan. On the same day, he acquired 12,500 shares for $181,250 through exercising stock options, also under a 10b5-1 plan. Despite a 359% surge in stock price over the past year, InvestingPro analysis suggests the stock is currently overvalued.
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics has announced the grant of inducement awards consisting of stock options to four non-executive employees. These awards, totaling 20,800 shares, were approved by the independent Compensation Committee on May 1, 2026, and were material to the employees' acceptance of employment. The options have a 10-year term, an exercise price of $69.42, and vest over a period of continuous service.
Pictet Asset Management Holding SA Cuts Stake in Spyre Therapeutics, Inc. $SYRE
Pictet Asset Management Holding SA reduced its stake in Spyre Therapeutics (NASDAQ:SYRE) by 11.8% in Q4, selling 122,258 shares. Despite this, other institutions like Vanguard increased their holdings, and hedge funds/institutions now own over 80% of the company. Spyre Therapeutics recently missed its quarterly EPS estimates, but analysts maintain an average "Buy" rating with a target price of $85.08.
Insider Sell: Cameron Turtle Sells 15,000 Shares of Spyre Therapeutics Inc (SYRE)
Cameron Turtle, CEO of Spyre Therapeutics Inc (SYRE), sold 15,000 shares of the company on May 1, 2026, increasing his total insider sells over the past year to 120,000 shares with no purchases. Following this transaction, he now holds 612,540 shares. Shares were trading at $71.37 each at the time of the sale, reflecting a market cap of $5,987.693 million.
Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) CFO Sells 12,500 Shares of Stock
Spyre Therapeutics (NASDAQ:SYRE) CFO Scott Burrows sold 12,500 shares of the company's stock on May 1st for a total of $892,125. This sale reduced his ownership by 11.31% to 97,994 shares. The transaction, conducted under a Rule 10b5-1 plan, occurs while the stock holds a consensus "Buy" rating and a price target of $85.08, despite recent negative EPS.
Spyre Therapeutics (NASDAQ:SYRE) Insider Sells $5,600,809.50 in Stock
An insider at Spyre Therapeutics (NASDAQ:SYRE), Sheldon Sloan, sold 78,333 shares of the company's stock on May 1st for a total of $5,600,809.50, executed under a pre-arranged Rule 10b5-1 trading plan. This transaction reduced his ownership by 50%. Despite this significant insider sale and the company missing its last quarterly EPS estimates, Wall Street analysts maintain a "Buy" rating for SYRE with an average target price of $85.08, compared to its recent trading price of $69.42.
Spyre Therapeutics (SYRE) CMO trades 78,333 shares under 10b5-1 plan
Spyre Therapeutics' Chief Medical Officer, Sheldon Sloan, reported trades involving the exercise of stock options for 78,333 shares and the simultaneous sale of the same number of shares on May 1, 2026. The sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted in June 2025, with weighted average selling prices ranging from $69.21 to $74.96 per share. After these transactions, 321,667 option shares from his original grant remain outstanding.
Spyre (SYRE) CFO sells 12,500 shares under Rule 10b5-1 plan
Spyre Therapeutics, Inc. (SYRE) CFO Scott L. Burrows sold 12,500 shares of common stock at $71.37 per share and simultaneously exercised stock options for 12,500 shares at an exercise price of $14.50 per share on May 1, 2026. These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 10, 2025. Following these actions, Burrows directly holds 110,494 shares, including restricted stock units and retains options for additional shares.
Spyre Therapeutics (SYRE) CEO executes 15,000-share Rule 10b5-1 sale
Spyre Therapeutics CEO Cameron Turtle sold 15,000 shares of common stock on May 1, 2026, through multiple open-market transactions conducted under a pre-arranged Rule 10b5-1 trading plan. The sales occurred at weighted-average prices ranging from $69.25 to $74.96 per share. Following these transactions, Cameron Turtle continues to hold 622,240 shares of Spyre common stock.
Spyre Therapeutics CFO Scott Burrows sells $892,125 in stock
Spyre Therapeutics CFO Scott Burrows sold 12,500 shares of company stock for $892,125 on May 1, 2026, under a pre-arranged trading plan, while also acquiring shares through stock option exercise. The sale occurred after a significant surge in the company's stock price, with analysts suggesting the stock may be overvalued. Burrows now directly holds 97,994 shares, including restricted stock units set to vest over the next two years.
Spyre Therapeutics CEO Cameron Turtle sells $1.07m in shares
Spyre Therapeutics CEO Cameron Turtle sold 15,000 shares of common stock totaling $1.07 million on May 1, 2026, under a Rule 10b5-1 trading plan. These sales occurred as SYRE shares traded near their 52-week high, following a 359% gain over the past year. Post-transaction, Turtle directly owns 612,540 shares, including those subject to future vesting.
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics, Inc. has granted stock options to four non-executive employees as inducement awards under its 2018 Equity Inducement Plan. These options, approved on May 1, 2026, allow employees to purchase an aggregate of 20,800 shares of common stock at an exercise price of $69.42 per share. The awards are structured to vest over four years, contingent on continuous employment, and were a material part of the employees' acceptance of their positions.
Spyre Therapeutics stock hits 52-week high at $75.30 By Investing.com
Spyre Therapeutics stock reached a 52-week high of $75.30, marking a 408% increase over the past year and bringing its market capitalization to $6.4 billion, though InvestingPro suggests it is overvalued. The company recently completed a public offering raising $463.5 million and received a "strong buy" rating from Raymond James with an $80 price target. This surge reflects strong investor confidence despite valuation concerns.
Spyre Therapeutics (SYRE) price target increased by 42.03% to 88.06
This article reports a significant increase in the price target for Spyre Therapeutics (SYRE). The target has been raised by 42.03% to $88.06.
JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $95
JonesTrading has reiterated its Buy rating on Spyre Therapeutics (SYRE.US), maintaining a price target of $95. This indicates a continued positive outlook from the firm regarding Spyre Therapeutics' stock performance and potential.
Spyre Therapeutics Secures $463.5 Million Through Public Stock Offering
Spyre Therapeutics Inc. successfully closed an underwritten public offering, raising approximately $463.5 million in gross proceeds. The biotechnology firm issued over seven million shares, including the full exercise of an option by underwriters, to fund medical research. The capital will be allocated towards developing long-acting antibodies and combination therapies for rheumatic conditions and inflammatory bowel disease.
Universal Beteiligungs und Servicegesellschaft mbH Raises Stake in Spyre Therapeutics, Inc. $SYRE
Universal Beteiligungs und Servicegesellschaft mbH significantly increased its stake in Spyre Therapeutics, Inc. by 55% in Q4, acquiring an additional 60,755 shares, bringing its total to 171,211 shares valued at $5.61 million. This move is part of a broader trend of institutional investors raising their holdings, with 80.39% of the stock now owned by hedge funds and other institutions. Despite insider selling by the CEO and CFO, analysts have aggressively raised price targets for SYRE, with a consensus "Buy" rating and an average target price of $85.08.
Spyre Therapeutics (SYRE) price target increased by 42.03% to 88.06
The price target for Spyre Therapeutics (SYRE) has been increased by 42.03% to 88.06. This adjustment indicates a significantly more optimistic outlook on the company's future stock performance.
Spyre Therapeutics (SYRE): Favorite Stock of Elite Money Managers
Spyre Therapeutics (SYRE) has become a favored stock among elite money managers due to its clinical successes in treating Inflammatory Bowel Disease (IBD). Its lead drug, SPY001, showed promising Phase 2 results for ulcerative colitis, and the company's strategy of combining best-in-class antibodies holds significant potential in the multi-billion dollar IBD market. Analysts believe Spyre could be a prime acquisition target for larger pharmaceutical companies.
SYRE stock jumps more than 70% in a month: What is driving this rally?
The SYRE stock has seen a significant rally of over 70% in the past month. This article aims to explore the potential reasons behind this sudden increase in its stock price, analyzing market trends, company news, and other relevant factors that might be contributing to its impressive performance.
Billionaire Joe Edelman’s 5 Stock Picks with Huge Upside Potential
This article highlights Spyre Therapeutics, Inc. (NASDAQ:SYRE) as one of billionaire Joe Edelman's top stock picks due to its huge upside potential. Spyre Therapeutics has shown promising clinical success for its drug SPY001 in treating ulcerative colitis, with analysts noting its potential superiority to existing treatments. The company's strategy of developing long-acting antibodies and combination therapies positions it as a strong acquisition target for Big Pharma in the growing Inflammatory Bowel Disease market.
Wall Street Zen Downgrades Spyre Therapeutics (NASDAQ:SYRE) to Sell
Wall Street Zen has downgraded Spyre Therapeutics (NASDAQ:SYRE) to a "sell" rating, despite a consensus "Buy" rating from other MarketBeat analysts with an average target price of $85.08. The downgrade follows Spyre Therapeutics' Q1 earnings miss and significant insider selling, though institutional ownership remains high at over 80%. Several firms, including BTIG, Wells Fargo, Deutsche Bank, and Raymond James, recently raised their price targets for SYRE.
Spyre Therapeutics prices upsized $403M stock deal; gross proceeds exceed initial $300M goal
Spyre Therapeutics has priced an upsized public offering of 33.6 million shares of its common stock, including prefunded warrants, at $12.00 per share and $11.99 per prefunded warrant. The gross proceeds from this offering are expected to be $403M, surpassing the initial target of $300M. The company plans to use these proceeds to advance its clinical pipeline.
